Table 1.

Characteristics of selected literature.

First author, year	Gender	Country	Patients (n)	Control group	Study group	Period (day)	Follow-up (day)
Hirakauva et al. [19], 2017	F	Brazil	217	Placebo qd (n = 63)	Levofloxacin 500 mg qd (n = 59), sulfamethoxazole 400 mg-trimethoprim 80 mg qd (n = 48), or nitrofurantoin 100 mg qd (n = 47)	1 d	14 d
Rahardjo et al. [17], 2016	F/M	Indonesia	126	Placebo qd (n = 63)	Levofloxacin 500 mg qd (n = 63)	3 d	4 d
Gürbüz et al. [20], 2013	F/M	Turkey	411	Blank control (n = 133)	Ciprofloxacin 500 mg qd (n = 141), or fosfomycin trometamol unknown dose qd (n = 137)	1 d	5-7 d
Siracusano et al. [26], 2008	F	Italy	262	Placebo qd (n = 132)	Norfloxacin 400 mg qd (n = 130)	1 d	3 d
Realfonso et al. [27], 2008	F	Italy	70	Placebo qd (n = 30)/blank control (n = 10)	Levofloxacin 500 mg qd (n = 30)	1 d	7 d
Kartal et al. [28], 2006	F/M	Turkey	192	Blank control (n = 94)	Ciprofloxacin 500 mg qd (n = 98)	1 d	2-3 d
Yip et al. [29], 2006	F	Hong Kong	130	Placebo (n = 65)	Amoxicillin 250 mg-clavulanic acid 125 mg qd (n = 65)	1 d	2 d
Peschers et al. [30], 2001	F	Germany	70	Placebo (n = 33)	Trimethoprim 320 mg-sulfamethoxazole 1600 mg qd (n = 37)	1 d	14 d
Darouiche et al. [16], 1994	F/M	USA	40	Placebo qd (n = 22)	Ciprofloxacin 500 mg bid (n = 18)	2 d	3-5 d
Baker et al. [14], 1991	F	Canada	102	Finapyridine 200 mg tid (n = 53);	Nitrofurantoin 50 mg q6h-finapyridine 200 mg tid (n = 49)	1 d	2-3 d
Coptcoat et al. [15], 1988	F/M	British	82	Blank control (n = 44)	Trimethoprim 200 mg qd (n = 38)	1 d	2 d
Tosto et al. [13], 1989	F	Italy	31	Blank control (n = 16)	Cinoxacin 500 mg bid (n = 15)	5 d	3-7 d
Bergman and McCarthy [9], 1983	F	USA	96	Finapyridine 100 mg tid (n = 45)	Nitrofurantoin 50 mg-finapyridine 100 mg tid (n = 51)	3 d	7 d